Breast Implants linked to a type of Lymphoma Cancer
Breast Implants linked to a type of Lymphoma Cancer (BIA- ALCL)
Breast Implants have been used for a number of years for the purposes of cosmetic surgery and also to provide reconstructive surgery after breast cancer. For many women, this has been a decision that has not been taken lightly, with the choice of implants used often based on the recommendations of the healthcare professional performing the surgery.
In July 2019, Allergan announced a worldwide recall of its unused Biocell Breast Implants, due to some reports of a rare Non- Hodgkins type Lymphoma occurring in women who had received the implants.
This Lymphoma is not a cancer of the breast itself but a cancer of the immune system. When identified early, the prognosis is good.
The Allergan Biocell implant is a textured implant which helps to keep the implant in place in the surrounding breast tissue. The Health Product Regulatory Authority cites medical journal findings which estimate one case of BIA-ALCL for every 3,345 of these specific implants used. There is also concern over tissue expanders manufactured by Allergan.
The BIOCELL surface was used in a range of Allergen breast implants including:
- Natrelle Inspira Textured (but not Natrelle Inspira Smooth)
- Natrelle 410 and 510
The HPRA identifies that these implants may have been previously marketed under brand names ‘McGhan’ or ‘Inamed’.
Other breast implants may also present a risk of developing BIA-ALCL, with some evidence suggesting a link to the amount of texturing on the surface of the implant.
The most common symptoms of BIA- ALCL are:
- A collection of fluid around one or both breast implants- this can occur many years after the surgical procedure.
- An increase in the size of the breast, due to the fluid collection
- Lumps near the breast implant or armpit
- Breast feeling unusually firm
In October 2019, The HSE contacted approximately 8000 Irish women who received these type of implants and tissue expanders, to warn them of the associated risks.
The average onset of this type of cancer is 8 years, however the HSE have identified that it can present anywhere between 1 year and 20 years after surgery.
If you, or family member have developed BIA-ALCL due to a textured breast implant, please call us and we will discuss the legal options available to you. Please contact us on 0212390620, email@example.com, or Hazel.firstname.lastname@example.org